Alex Ruth, Gulam Shabaz Mohiuddin, Kumar Kiran
College of Pharmacy, Gulf Medical University, Ajman, UAE.
Dept. of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, UAE.
Adv Virol. 2022 Jun 9;2022:7060466. doi: 10.1155/2022/7060466. eCollection 2022.
Coronavirus disease 2019 (COVID-19) can progress to severe respiratory compromise and lead to mortality due to induction of cytokine storm. Tocilizumab (TCZ) is approved by the FDA for the treatment of cytokine release syndrome (CRS). This study aims to analyze the outcomes among patients who received TCZ in the United Arab Emirates.
A retrospective cohort study was conducted among COVID-19 patients who received TCZ in a tertiary care hospital from May 2020 to August 2021. For analysis, patients were divided into two groups based on survival and clinical improvement.
Overall, 80% of patients receiving TCZ were discharged by day 28. There was a gradual improvement in oxygen requirements in our patients with a majority of them on room air by day 28. Age more than 50 years (=0.034) and comorbidities such as cardiovascular disease (CVD) (=0.002) and renal insufficiency (=0.013) were significantly associated with mortality. . In our analysis, patients who were mechanically ventilated at the time of administration of TCZ had a significantly higher risk of death by day 28. In both survived and improved groups, younger patients had better outcomes than older patients. Patients who received TCZ earlier during therapy from the onset of symptoms had better survival outcomes. There was only one death among 14 patients who received vaccination. There was no significant difference in mortality among patients with comorbidities such as diabetes, hypertension, dyslipidemia, obesity, and pulmonary diseases, hypothesizing that administration of TCZ improves the outcomes in COVID-19 patients with these comorbidities.
2019年冠状病毒病（COVID-19）可进展为严重的呼吸功能不全，并因细胞因子风暴的诱导而导致死亡。托珠单抗（TCZ）已获美国食品药品监督管理局（FDA）批准用于治疗细胞因子释放综合征（CRS）。本研究旨在分析在阿拉伯联合酋长国接受TCZ治疗的患者的治疗结果。
对2020年5月至2021年8月在一家三级护理医院接受TCZ治疗的COVID-19患者进行了一项回顾性队列研究。为进行分析，根据生存情况和临床改善情况将患者分为两组。
总体而言，80%接受TCZ治疗的患者在第28天出院。我们的患者对氧气的需求逐渐改善，到第28天时，大多数患者可在室内空气中呼吸。年龄超过50岁（=0.034）以及患有心血管疾病（CVD）（=0.002）和肾功能不全（=0.013）等合并症与死亡率显著相关。在我们的分析中，在给予TCZ时接受机械通气的患者在第28天死亡的风险显著更高。在存活和病情改善的两组患者中，年轻患者的治疗结果均优于老年患者。在治疗过程中从症状出现时起更早接受TCZ治疗的患者生存结果更好。在14名接种疫苗的患者中仅有1例死亡。患有糖尿病、高血压、血脂异常、肥胖症和肺部疾病等合并症的患者死亡率无显著差异，推测给予TCZ可改善患有这些合并症的COVID-19患者的治疗结果。
